Download - Local Biotechs: Unleash the Power
Presentation
“Local Biotechs: Unleash the Power ”
By
Joseph C. K. LiuMBA, Ph.D
China Concord Limited
20 August 2016
HK Polytechnic University
Selected Diagnostics Companies in HKSTP
SanWa Biotech: IVD, ALiA (Array Based LED induced fluorescence ImmunoAssay platform, Lab-On-Chip (LOC) platform)
Amvet Biosciences: Animal genetic DNA testing
Arbele Biopharmaceutica (CUHK): Therapeutics for GI & lung malignancies
GemVCare (CUHK): Hong Kong based genetic testing target diabetes
Hai Kang Life: Lab-On-a-Chip (LOAC) - Platform detect target genes
BerryGenomics (Beijing): DNA sequencing technologies to prenatal & cancer clinical genetic test
HSK GeneTech (CUHK): Genomics and hi-throughput sequencing in Food Research and Core Facilities of Genome Research
KingMed Diagnostics: Medical diagnostics testing, clinical trial testing, medical research services and hygiene testing, molecular diagnostic techniques to detect, identify and quantify infectious agents
Living Tissues Company (HKU): Tissue Engineering Laboratory, Living Tissues use the donor's stem cells and grow a complex tissue plug
Selected Diagnostics Companies in HKSTP(Cont’d)
NanoBioImaging Ltd (UST): Super resolution microscopic bio-imaging
Novus Life Sciences (HKU): Orthobiologics, injectable biomaterial for minimal invasive surgery, biomaterials formulation in repairing bone and cartilage
OncoSeek(HKU): Cancer diagnostics for personalized cancer screening assays thru advanced biomedical technology, early and real-time screening of invasive cancer & personalized non-invasive cancer screening assays
Oper Tech (HKBU): Nanomaterial-based personalized medicine, nanomedicine: 1. Individualized stem cell therapy 2. Novel surgical technology 3. Nanodrugs 4. personalized medicine (2016 Grand Prix at 44th Geneva International Exhibition of Inventions Award)
Sonikure Technology (UST): Intravitreal injection for retinal diseases, deliver drugs in eye with low energy and low intensity ultrasonic technology
Xcelom(CUHK): T21 prenatal diagnostics, genomics technology for genetic sequencing innovations
Statistics of Local Diagnostic Co’s.
Tot. 38 Co’s currently in HKSTP
15 from local universities (40%)
CUHK (4, 27%), HKU(3, 20%), UST (2, 13%), HKBU(1, 7%)
CityU spinoffs not listed because they either graduated earlier or never admitted in HKSTP incubation/regular tenant program
Examples of Local High-Fliers
Prof. Dennis Lo (CUHK):
Arbele and Xcelom
Prof. Michael Yang (CityU):
Multigene Diagnostics Ltd., GenetelPharmaceuticals Ltd, Prenetics
Prof. Cheng, Shuk Han(CityU):
Vitargent (International) Biotechnology
Professor Lo Yuk Ming, Dennis (CUHK)
Director of the Li Ka Shing Institute of Health Sciences (CUHK)
Numerous publications in Nature & Science magazines among local academia (Pic 1)
Xcelom: Non-invasive Prenatal Test for Down Syndrome, 'safeT21' (sensitive analysis of fetal DNA for T21 screening) vs invasive procedures such as amniocentesis and chorionic villus sampling (0.5% to 1% chance of pregnancy miscarriage)
Arbele Biopharmaceutical: screening for signs of cancer from a simple blood draw
Professor Yang Mengsu,Michael (CityU)
Multigene Diagnostics Ltd., molecular diagnostics for early detection of diseases
Genetel Pharmaceuticals Ltd., DNA diagnostic technology (SNIPERTM-HPV early detection of the human papillomavirus, causes all cases of cervical cancer), Bio-sensor, DNA diagnostic technology for the early detection of cervical cancer
“Technological Achievement Grand Award” for cervical cancer diagnostic technology in the 2006 Hong Kong Awards
Prenetics: Next generation DNA testing, US $ 10M invested by Ping An Venture & run by Danny Yeung (ex-Groupon CEO), partner with Prudential Insurance
Professor Cheng Shuk Han (CityU)
CityU SpinOff: Vitargent (International) Biotechnology
Venture Investor: WI Harper Group
2014 Hong Kong Awards for Industries —Technological Achievement Award
2015 Grand Prix at 43rd Geneva International Exhibition of Inventions Award
Technology: Patented first-in-the-world transgenic medaka and zebrafish fish embryo toxicity (FET) test
New global pdt safety std. detect toxin 24/48h
Home grown Bio-testing innovation
Hong Kong X-Tech Start-Up Foundation(16 July 2016)
Local Manufacturer From OEM to IPO
Vincent Medical (HKSE Code: 1612, 7/’16 IPO) Medical Equipment &
Services in Dongguan, Chairman Mr. Choi Man Shing(蔡文成, 60 %)
IPO (July 2016) $1/share, Range $0.79-1.26, Mkt Cap HK $ 520M, revenue $ 448M, Net Profit $ 58M (‘15)
OEM for Bayer Medical Care(87%, Inspired Medical (英仕醫療) own brand 13%) respiratory products (39%), imaging contrast media power injector disposable products (35%), orthopaedic (16%),rehabilitation (10%)
Disposable for deliver humidify gases to patients under ventilation/oxygen
2nd largest exporter of respiratory and anaesthesia disposables in the PRC
Critical successful factor: QA/QC, Certification, expand domestics (380 domestic distributors network) & overseas mkt (42 distributors), sterilisation for Med. Device, Hi/low margin pdts, move from OEM to OBM
Relation of Molecular Diagnostics to Other Technologies
Future Biotech Trend
More personalized, predictable, preventive medicine (3Ps)
Target therapies & molecular diagnostics
Concerns: drug safety, ageing population, bioterrorism, pandemics, healthcare cost
Best time for Biotechs and worse for big pharma
Successful factors, robust product pipeline and diversity
What’s driving “Personal Medicine” ?
New technologies (system biology)
Aging population (US, Europe, Japan, PRC)
Managed care/insurance, little room for “me-to” drugs due to cost, more drugs use vs expensive hospital care
Access to “healthy foods” i.e. health supplements
Obstacles for Personalized Medicine
Barriers between drug and device companies
Regulatory challenges
Bioethical questions
Patient privacy & insurance coverage for diagnostic tests
Screening tumors for cancer-related gene abnormalities
Cancer therapy will be guided by the particular set of genetic mutations within each patient's tumor.(Massachusetts Institute of Technology and Harvard University, Science Feb 13, 2007)
Example (I) Novel Design: Plastics Dish
Example of Novel Design: Bio-reactor Electronic & Mechanical
Example (II) Novel Design: Original Diagnostics Unit
Example of Novel Design: Renovated Diagnostics Unit
Example (III) Start-Up Biotech Co.
Example (IV): Anti-fouling Agent Market (Boat Bottom Paint, Marine Coating)
Apply to all vessels floating (anti-fouling agent 5% added to underwater paint)
Microbial attach/grow to bottom of vessel reduce speed, fuel cost, shipping time for cargo, vessel back to wharf for service every 3-4 years
Environmental concern: Copper not allow, biohazard to ocean wildlife
China gross tonnage 22,682k (‘14)
Example of Local Tech Transfer Anti-fouling Agent
PRC Ship Paint Market 2010/11
Estimate Fuel Consumption
Inhibition Effect for 3 Major Microbials
Is this a Drug ?
Example (V): Novel Med.Pdt Co.
Canadian Co. specialize in Anti-adhesion for post-surgical procedures
Natural extracts from sea-weed
FDA approved as “medical devices” instead of drug to avoid tedious & costly clinical trials & regulation
Performance-based Competitive Advantage:Rabbit Model of Surgical Adhesions
Control instillate
Uterine hornsfirmly adhered
ARCADTM Instillate
No adhesions
Uterus
Abdominal wall
Adhesions
2
Injury
Inflammation
Coagulation
Resolution
Proliferation
Surgical Adhesion Normal Healing3
0
4
6
8
ControlLRS
FucoidanInstillate
Adhesi
on s
everity
sco
re
*
8
10
12
14
16
18
20
2
0
1
2
3
4
Num
ber
of
adhesi
ons
*
5
6
7
8
9
10
ControlLRS
FucoidanInstillate
Fucoidan Instillate™ has Compelling Efficacy and Safety Data in Foal Model of Surgical Adhesions
Would you like to have this Check ?
Four “Smarts”
People
Ideas
Money
Alliances & partnership
Medical Device Successful Footprints
License a patent
Build a prototype
Finish a clinical trial
Sell the technology
Local Technology Transfer Consideration
1. Individual faculty’s research project
2. University Knowledge Transfer Office
3. Licensing agreement: sold off or royalty/profit split, risk ? University involvement ?
4. Split of interest: university, department, research team: faculty, research fellows, if any
Motto of Biotech
"There are only two kinds of biotech companies -- those that have had disappointments and those that will have disappointments in the future, the successful ones are those that work through their disappointments''
(Love, the chief executive, Nuvelo Pharma)
Do you have a role in this Biotech bandwagon ?
The Destiny is in our hands
Thank you !